IGHE and parasitic infectious disease: Addressing other cytokines or chemokines that are involved in the molecular pathway of equine IBH (e.g. IL-4 and IL-13 for B cell class switch) could lead to a broader less specific immune reaction and a potential therapy against IgE, like Omalizumab for humans, could result in an increased risk for parasite infections.